WuXi PharmaTech Set To Compete Globally Following OECD Certification Of New Drug Toxicology Lab In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Armed with a new certification on good laboratory practice compliance from the Organization for Economic Cooperation and Development, WuXi PharmaTech's preclinical testing facility could be poised to battle the globe's giants in providing toxicology services for international players
You may also be interested in...
Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma
BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai
Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma
BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai
Despite Inflationary Headwinds, Chinese CRO WuXi PharmaTech Set To Ride Wave Of Global Outsourcing
BEIJING - Leading Chinese contract research organization WuXi PharmaTech will face inflationary pressure on profits this year, but stepped-up outsourcing of research to China by international pharmaceutical players and the Shanghai-based firm's expanding range of services are likely to ensure strong earnings through 2011 and beyond, according to a prominent analyst who monitors the country's healthcare sector